Chemotherapy increases risk of mild cognitive deficits in breast cancer patients

NewsGuard 100/100 Score

A large meta-analysis conducted by researchers at Moffitt Cancer Center has concluded that breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits after treatment. The meta-analysis, or analytic review of previously published studies, found that study participants on average had mild impairments in verbal abilities (such as difficulty choosing words) and visuospatial abilities (such as getting lost more easily). The study noted that cognitive functioning varies across survivors, with some reporting no impairments and others reporting more severe or pervasive deficits.

The study was published in a recent issue of the Journal of Clinical Oncology. The research was supported in part by the National Cancer Institute, part of the National Institutes of Health, through grant number K07 CA138499.

"The objective of our analysis was to clarify existing research on cognitive functioning in patients who had received standard dose chemotherapy for breast cancer at least six months previously," said study lead author Heather S.L. Jim, Ph.D., an assistant member at Moffitt whose research focuses on the psychosocial and behavioral aspects of cancer survivorship. "Earlier studies had reported conflicting evidence on the severity of cognitive deficits, especially over the long term."

Although this is an active area of research, an overall analysis of the studies had not been performed since 2006, explained the researchers.

"Our analysis indicated that patients previously treated with chemotherapy performed significantly worse on tests of verbal ability than individuals without cancer," noted co-author Paul B. Jacobsen, Moffitt senior member and associate center director of Population Sciences. "In addition, patients treated with chemotherapy performed significantly worse on tests of visuospatial ability than patients who had not had chemotherapy."

"Breast cancer patients treated with chemotherapy who have subsequent cognitive deficits should be referred to a neuropsychologist for evaluation and management of the deficits," Jim said. "Management usually involves developing an awareness of the situations in which their cognitive difficulties are likely to arise so that they can come up with strategies to compensate. Research shows that such strategies can make a big difference in daily life when cognitive difficulties do arise."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning models identify immunophenotypes in NSCLC for immunotherapy guidance